États-Unis · Plateformes & données · MarketBeat

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Publié par MarketBeat · États-Unis il y a 1 h

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

À lire aussi

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants

Is Record Low Pending Home Sales Altering The Investment Case For Rocket Companies (RKT)?

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Partager

À lire aussi

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants

Is Record Low Pending Home Sales Altering The Investment Case For Rocket Companies (RKT)?